Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCL-IPM1
- Development stage
- Phase 1
- Lead developer
- Vical
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VCL-IPM1 is a monovalent DNA plasmid vaccine developed by Vical Incorporated for the prevention of pandemic influenza, specifically targeting the H5N1 strain. The vaccine consists of a plasmid encoding the hemagglutinin (HA) surface protein from the A/Vietnam/1203/2004 (H5N1) influenza virus. It was designed to be administered using the Biojector 2000 needle-free system, which facilitates the delivery of the DNA into host cells to induce both humoral (antibody) and cellular (T-cell) immune responses. The development of VCL-IPM1 was part of a broader pandemic preparedness initiative, but clinical development was discontinued following early-phase testing and the company's subsequent restructuring.
- Other names
- H5N1 DNA vaccineH-5N1 DNA vaccineH 5N1 DNA vaccineVical H5N1 influenza DNA vaccine
02
Targets
M2 (Matrix protein 2)NP (Influenza A virus nucleoprotein)HA (Hemagglutinin)
Beyond the preview
Go deeper on VCL-IPM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCL-IPM1.